Anticancer activity of novel pyrido[2,3-b] indolizine derivatives: The relevance of phenolic substituents

Anticancer Research

Volumn 34, Issue 4, 2014, Pages 1673-1678

  Boot, Arnoud ^a   Brito, Alexandra ^a,b   Van Wezel, Tom ^a   Morreau, Hans ^a   Costa, Marta ^b   Proença, Fernanda ^b  

^a LEIDEN UNIVERSITY MEDICAL CENTER   (Netherlands)

^b UNIVERSITY OF MINHO   (Portugal)

Author keywords

Cell cycle; Colorectal cancer; Cytotoxicity; HCT116; HT 29 and RKO cell lines; Indolizine derivatives

Indexed keywords

4 (3,4) DIHYDROXYPHENYL) 2 PHENYLPYRIDO[2,3B]INDOLIZINE 10 CARBONITRILE; ANTINEOPLASTIC AGENT; INDOLIZINE DERIVATIVE; UNCLASSIFIED DRUG; INDOLIZINE; PHENOL DERIVATIVE;

ANTINEOPLASTIC ACTIVITY; ARTICLE; BIOASSAY; BIOLOGICAL ACTIVITY; CARBON NUCLEAR MAGNETIC RESONANCE; CELL CYCLE G2 PHASE; CELL CYCLE M PHASE; CELL CYCLE PROGRESSION; CELL CYCLE S PHASE; CELL VIABILITY; COLORECTAL CANCER CELL LINE; CONTROLLED STUDY; DRUG SYNTHESIS; FIBROBLAST CULTURE; FLOW CYTOMETRY; GROWTH INHIBITION; HUMAN; HUMAN CELL; CELL CYCLE; CELL SURVIVAL; CHEMISTRY; COLORECTAL CANCER; COLORECTAL TUMOR; CYTOTOXICITY; DOSE RESPONSE; DRUG EFFECT; HCT116; HCT116 CELL LINE; HT 29 CELL LINE; HT-29 AND RKO CELL LINES; IC 50; INDOLIZINE DERIVATIVES; TUMOR CELL LINE;

CELL CYCLE; COLORECTAL CANCER; CYTOTOXICITY; HCT116; HT-29 AND RKO CELL LINES; INDOLIZINE DERIVATIVES;

ANTINEOPLASTIC AGENTS; CELL CYCLE; CELL LINE, TUMOR; CELL SURVIVAL; COLORECTAL NEOPLASMS; DOSE-RESPONSE RELATIONSHIP, DRUG; HCT116 CELLS; HT29 CELLS; HUMANS; INDOLIZINES; INHIBITORY CONCENTRATION 50; PHENOLS;

EID: 84902241819     PISSN: 02507005     EISSN: 17917530     Source Type: Journal    
DOI: None     Document Type: Article

References (23)

1. Ferlay J, Shin HR, Bray F, Forman D, Mathers C and Parkin DM: Estimates of worldwide burden of cancer in 2008: GLOBOCAN 2008. Int J Cancer 2010.
2. Migliore L, Migheli F, Spisni R, and Coppede F: Genetics, cytogenetics, and epigenetics of colorectal cancer. J Biomed Biotechnol 2011: 792362, 2011.
3. Haydon AM and Jass JR: Emerging pathways in colorectal-cancer development. Lancet Oncol 3: 83-88, 2002.
4. Kambara T, Simms LA, Whitehall VL, Spring KJ, Wynter CV, Walsh MD, Barker MA, Arnold S, McGivern A, Matsubara N, Tanaka N, Higuchi T, Young J, Jass JR and Leggett BA: BRAF mutation is associated with DNA methylation in serrated polyps and cancers of the colorectum. Gut 53: 1137-1144, 2004.
5. Bardelli A and Siena S: Molecular mechanisms of resistance to cetuximab and panitumumab in colorectal cancer. J Clin Oncol 28: 1254-1261, 2010.
6. Laurent-Puig P, Cayre A, Manceau G, Buc E, Bachet JB, Lecomte T, Rougier P, Lievre A, Landi B, Boige V, Ducreux M, Ychou M, Bibeau F, Bouche O, Reid J, Stone S and Penault-Llorca F: Analysis of PTEN, BRAF, and EGFR status in determining benefit from cetuximab therapy in wild-type KRAS metastatic colon cancer. J Clin Oncol 27: 5924-5930, 2009.
7. Arnold D and Seufferlein T: Targeted treatments in colorectal cancer: state of the art and future perspectives. Gut 59: 838-858, 2010.
8. Cunningham D, Atkin W, Lenz HJ, Lynch HT, Minsky B, Nordlinger B and Starling N: Colorectal cancer. Lancet 375: 1030-1047, 2010.
9. El-Sharief MA, Moussa Z and El-Sharief AM: Synthesis and biological evaluation of bis-imidazolidineiminothiones: a comparative study. Arch Pharm (Weinheim) 346: 542-555, 2013.
10. Shen YM, Lv PC, Chen W, Liu PG, Zhang MZ and Zhu HL: Synthesis and antiproliferative activity of indolizine derivatives incorporating a cyclopropylcarbonyl group against Hep-G2 cancer cell line. Eur J Med Chem 45: 3184-3190, 2010.
11. James DA, Koya K, Li H, Liang G, Xia Z, Ying W, Wu Y and Sun L: Indole- and indolizine-glyoxylamides displaying cytotoxicity against multidrug resistant cancer cell lines. Bioorg Med Chem Lett 18: 1784-1787, 2008.
12. Asano N, Nash RJ, Molyneux RJ and Fleet GWJ: Asano, N. Sugar-mimic glycosidase inhibitors: natural occurrence, biological activity and prospects for therapeutic application. Tetrahedron: Asymmetry 11: 1645-1680, 2000.
13. Malonne H, Hanuise J and Fontaine J: Topical anti-inflammatory activity of new 2-(1-indolizinyl)propionic acid derivatives in mice. Pharm Pharmacol Commun 4: 241-243, 1998.
14. Kitadokoro K, Hagishita S, Sato T, Ohtani M and Miki K: Crystal structure of human secretory phospholipase A2-IIA complex with the potent indolizine inhibitor 120-1032. J Biochem 123: 619-623, 1998.
15. Gundersen LL, Negussie AH, Rise F and Ostby OB: Antimycobacterial activity of 1-substituted indolizines. Arch Pharm (Weinheim) 336: 191-195, 2003.
16. Gundersen LL, Charnock C, Negussie AH, Rise F, and Teklu S: Synthesis of indolizine derivatives with selective antibacterial activity against Mycobacterium tuberculosis. Eur J Pharm Sci 30: 26-35, 2007.
17. Huang W, Zuo T, Jin H, Liu Z, Yang Z, Yu X, Zhang L and Zhang L: Design, synthesis and biological evaluation of indolizine derivatives as HIV-1 VIF-ElonginC interaction inhibitors. Mol Divers 17: 221-243, 2013.
18. de Bolle L, Andrei G, Snoeck R, Zhang Y, Van LA, Otto M, Bousseau A, Roy C, De CE and Naesens L: Potent, selective and cell-mediated inhibition of human herpesvirus 6 at an early stage of viral replication by the non-nucleoside compound CMV423. Biochem Pharmacol 67: 325-336, 2004.
19. Medda S, Jaisankar P, Manna RK, Pal B, Giri VS, and Basu MK: Phospholipid microspheres: a novel delivery mode for targeting antileishmanial agent in experimental leishmaniasis. J Drug Target 11: 123-128, 2003.
20. Lillelund VH, Jensen HH, Liang X and Bols M: Recent developments of transition-state analogue glycosidase inhibitors of non-natural product origin. Chem Rev 102: 515-553, 2002.
21. Chaniyara R, Tala S, Chen CW, Zang X, Kakadiya R, Lin LF, Chen CH, Chien SI, Chou TC, Tsai TH, Lee TC, Shah A and Su TL: Novel antitumor indolizino[6,7-b]indoles with multiple modes of action: DNA cross-linking and topoisomerase I and II inhibition. J Med Chem 56: 1544-1563, 2013.
22. Costa M, Areias F, Castro M, Brea J, Loza MI and Proenca F: Synthesis of novel chromene scaffolds for adenosine receptors. Org Biomol Chem 9: 4242-4249, 2011.
23. Chowdhury SA, Kishino K, Satoh R, Hashimoto K, Kikuchi H, Nishikawa H, Shirataki Y and Sakagami H: Tumor-specificity and apoptosis-inducing activity of stilbenes and flavonoids. Anticancer Res 25: 2055-2063, 2005.